JP2018020971A - Composition for enhancing expression of adiponectin - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a composition using biomass for enhancing expression of adiponectin.SOLUTION: The present invention provides a composition for enhancing expression of adiponectin, containing testis extract. Preferably, the composition further contains soy isoflavone. More preferably, in the composition, a mass ratio between soy isoflavone and testis extract is 1:0.3-7.0.SELECTED DRAWING: None

Description

  The present invention relates to a composition for enhancing expression of adiponectin. The composition of the present invention can be used for the enhancement of adiponectin expression and the maintenance and improvement of biological functions that are improved by the enhancement of adiponectin expression. The present invention is useful in fields related to general foods, health foods, health, beauty, and medicine.

  Adiponectin is a hormone secreted by fat cells discovered by the Osaka University School of Medicine in 1996, and its blood concentration is orders of magnitude higher than the blood concentration of general hormones of several ng / ml. Reach the μg / ml order. As for adiponectin, a great many functions are known, for example, promotion of sugar uptake utilization, fat degradation, blood vessel dilation, blood vessel repair, and tumor growth inhibition. Therefore, an increase in the blood concentration of adiponectin is expected to have effects on diabetes, hyperlipidemia, hypertension, arteriosclerosis, cancer and the like. Adiponectin is considered to be a key molecule for the prevention of metabolic syndrome, and there is a report that a diet that increases adiponectin showed an anti-metabolic syndrome effect without dietary and exercise restrictions (Non-patent Document 1).

  Some food ingredients have been reported to have an effect of increasing adiponectin, or an anti-metabolic syndrome effect and an effect on type 2 diabetes and obesity related to the metabolic syndrome. For example, Patent Document 1 is a nutritional composition containing protein, lipid and carbohydrate, and the energy ratio is 10 to 25% protein, 10 to 35% lipid and 40 to 60% carbohydrate, and the energy of lipid. Proposing a composition for enhancing production of PPAR and / or PPAR-related factor, wherein oleic acid ester in the ratio is 60 to 90% and palatinose and / or trehalulose in the sugar energy ratio is 60 to 100%. It states that impaired glucose tolerance, type 2 diabetes and obesity can be treated or prevented by the insulin resistance and obesity improving effects of the composition. Patent Document 2 proposes an adiponectin elevating agent containing phosphatidylinositol. Patent Document 3 describes a metabolic syndrome comprising at least one amino acid having a glucagon secretion enhancing action, at least one xanthine derivative, at least one isoflavone, and at least one carnitine or carnitine precursor. Proposal of a preventive, ameliorating or therapeutic composition. Patent Document 4 proposes a composition containing chalcone and isoflavone of tomorrow and states that this composition exhibits an excellent adiponectin production-inducing action.

  On the other hand, pork testicles are food ingredients that have been used in various cuisines overseas, and extracts extracted from pork testicles as a raw material have testosterone secretion promoting function in rats, spermatogenesis promoting function in rats, An exercise endurance improving function and the like have been confirmed (Non-patent Document 2). However, the testicular extract is not known to have an effect of increasing adiponectin.

International Publication WO2006 / 006286 JP 2008-291002 A International Publication WO2008 / 093826 JP 2011-190245 A

Miki Okada-Iwabu et al., A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity, Nature 503, 493-499 (28 November 2013) doi: 10.1038 / nature12656 Muneshige Shimizu et al., Nourishing tonic effect of pork testis extract “P-Testis”, Food style 21, 11 (4), 46-48, 2007-04, Food Chemical Newspaper

  Metabolic syndrome, which has been reported to increase in recent years, has been found to trigger various diseases, and countermeasures are urgently needed.

  The present inventors have been working on research and development of foods and materials useful for health by utilizing biological resources. Among them, the present object is to find a component having an effect of preventing and improving metabolic syndrome and related diseases.

The present invention provides the following.
[1] A composition for enhancing expression of adiponectin, comprising testicular extract.
[2] The composition according to 1, further comprising soybean isoflavone.
[3] The composition according to 2 or 3, wherein the mass ratio of soy isoflavone and testicular extract is 1: 0.3 to 7.0.
[4] A combination of soy isoflavone and testicular extract for enhancing adiponectin expression.
[5] The combination according to 4, wherein the mass ratio of soy isoflavone and testicular extract is 1: 0.3 to 7.0.
[6] The composition or combination according to any one of 1 to 5 for treating metabolic syndrome and diabetes and cardiovascular diseases related thereto.

Adiponectin expression enhancing effect of food-derived materials. In porcine testicle extract (PT), a remarkable enhancement effect of adiponectin was confirmed. Comparison of adiponectin expression enhancing effect between PT and daidzein. PT enhanced adiponectin expression in a concentration-dependent manner up to 5 mg / ml, which exceeded the effect of daidzein. The effect of the combination of PT and daidzein. Simultaneous addition of PT and daidzein synergistically enhanced the desired effect.

[Active ingredients]
The present invention relates to the use of testicular extract and the combined use of soy isoflavone and testicular extract to enhance the expression of adiponectin.

(Testicular extract)
One of the active ingredients in the present invention is testicular extract. The testicle extract refers to an extract extracted from the testicles as the raw material. The testicle extract is typically a liquid obtained by removing solids from a liquid material obtained by subjecting the raw material to operations such as enzymatic decomposition, extraction with an appropriate solvent, and pressing. It can be any of oil, paste, gel, liquid, solid, powder and the like. The testicle extract may be subjected to steps such as rough purification and sterilization.

  The testicle extract can be produced using a known method used for obtaining an extract from an animal sample. The raw material can be obtained from various animals, for example, pigs, cows, goats, wild boars and the like. The raw material can be washed and cut as necessary. The production process includes, for example, enzymatic decomposition, enzyme deactivation, filtration, concentration, sterilization, and drying. Enzymatic degradation is, for example, by hydrolysis with proteases. The protease used is acceptable for the production of foods, pharmaceuticals or cosmetics, and is not particularly limited as long as it can degrade proteins. For example, papain, trypsin, pepsin, bromelain, thermolysin, etc. It can be illustrated. Two or more proteases may be used in combination. The enzyme deactivation treatment is, for example, by heating to a sufficient temperature. The obtained enzyme degradation product of the raw material may be filtered using activated carbon, diatomaceous earth or the like as necessary to remove solids, or may be roughly purified. The filtrate or the crude product may be further concentrated by evaporating water by heating. The obtained concentrate is sterilized as necessary, and may be further dried to a powder by a conventional drying means such as hot air drying, spray drying, freeze drying and the like.

(Soy isoflavone)
Soy isoflavone is a general term for isoflavones contained in soybean. Soy isoflavones include daidzein, genistein, and glycitein, which are non-glycosides (aglycones), and the glycosides, genistin, daidzin, and glycitin. The composition of the present invention may be used alone or in combination of two or more. An example of a preferred soy isoflavone is daidzein.

  Daidzein is a compound represented by the following formula.

  In the present invention, a plant extract, a crude product, an isolated product, a purified product, or a synthetic product can be used as soybean isoflavone.

  In the present invention, when the amount, concentration, and ratio of soybean isoflavone are represented by numerical values, they are values as an aglycon unless otherwise specified. When a plurality of components are used as soybean isoflavones, the amount, concentration, and ratio of soybean isoflavones refer to the total amount and concentration based on the total amount of the plurality of components, unless otherwise specified.

  When converting from soy isoflavone glycoside to soy isoflavone aglycone, it can be determined from the ratio of the molecular weight of glycoside to aglycone. For convenience, the conversion from soy isoflavone glycoside to soy isoflavone aglycone is the most highly estrogenic activity genistein (molecular weight (270.24) and molecular weight of genistin (432.38)). For example, 10 mg of soybean isoflavone glycoside can be converted to 6.25 mg as soybean isoflavone aglycone.

[Use and function]
The composition of the present invention can be used for enhancing expression of adiponectin. Enhancing expression of adiponectin includes increasing the blood concentration of adiponectin and increasing mRNA expression of adiponectin. According to the present invention, adiponectin expression can be enhanced while suppressing the intake of soybean isoflavone by combining with the testicle extract.

  The presence / absence and degree of adiponectin expression enhancing action can be evaluated using cultured cells, as shown in the Examples section of this specification. Various cells derived from various animals can be used as the cultured cells. For example, cells related to adipose tissue such as a preadipocyte cell line are preferably used.

  The compositions of the invention can also be used for the treatment of diseases or conditions associated with enhanced adiponectin expression, including pathological and non-pathological conditions. For example, it can be used for the treatment of metabolic syndrome, diabetes and cardiovascular disease strongly associated with it.

  The term “treatment” for a disease or condition in the present invention includes reduction of risk of onset, delay of onset, prevention, treatment, stop of progression, and delay. The treatment includes medical actions performed by doctors for the treatment of illnesses and non-doctors such as dietitians (including registered dietitians and sports dietitians), sports instructors, professional athletes (athletes), public health nurses, This includes non-medical acts performed by midwives, nurses, clinical laboratory technicians, beauty staff, estheticians, food manufacturers, food sellers, etc. Treatment also includes recommendations for the administration or intake of specific foods, dietary guidance, health guidance, nutrition guidance (nutrition guidance necessary for medical treatment for the sick and disabled, and nutrition guidance for health maintenance and promotion. .), Including guidance necessary for improving nutrition related to school lunch management and school lunch. The subject of treatment in the present invention includes humans (individuals), and is preferably a human in whom it is desirable to perform any of the above-mentioned treatments or in need of any of the above-mentioned treatments.

  During treatment, the subject is ingested (administered, sometimes used) with testicular extract or soy isoflavone and testicular extract. A person skilled in the art can appropriately design the amount to be ingested according to the age, weight, sex, applied disease or condition of the subject.

  The testicular extract intake can be, for example, 1 mg / day or more, preferably 5 mg / day or more, more preferably 10 mg / day or more, and 20 mg / day or more. More preferably. Moreover, it may be 25 mg / day or more, 50 mg / day or more, 100 mg / day or more, or 200 mg / day or more. In any case, it may be 1,000 mg / day or less, 700 mg / day or less, or 400 mg / day or less. As the testicle extract, the above-mentioned daily intake may be taken at once, or may be taken divided into multiple times. It should be noted that in the present invention, when expressing the amount of testicular extract, it is described in the amount of testicular extract powder obtained by enzymatic degradation, enzyme deactivation, filtration, concentration, sterilization, and drying. doing. For example, as long as the amount of P-Testis (manufactured by Nippon Ham Co., Ltd., hereinafter also referred to as PT) is within a predetermined range related to the amount of testicular extract described herein, it is included in the scope of the present invention. . When other testicular extract is used, when converted into PT using the amount of components, solid content, etc. contained in PT as an index, the converted value is within a predetermined range for the amount of testicular extract described in this specification. As long as they are included in the scope of the present invention.

  The intake of soy isoflavone can be, for example, 5 mg / day or more, preferably 10 mg / day or more, more preferably 15 mg / day or more, and 20 mg / day or more. More preferably. Regardless of the lower limit, it can be 180 mg / day or less, preferably 120 mg / day or less, more preferably 60 mg / day or less, and 30 mg / day or less. More preferably. As soy isoflavone, the above-mentioned daily intake may be taken at once, or may be taken divided into a plurality of times.

  When ingesting a combination of soy isoflavone and testicular extract, the mass ratio of soy isoflavone and testicular extract can be 1: 0.3 to 7.0, and 1: 0.5 to 6.0. Is preferably 1: 1.0 to 5.0, more preferably 1: 1.2 to 4.0, and further preferably 1: 1.3 to 2.0. preferable. Ingestion in combination refers to ingestion to be absorbed at the same time, including ingestion of two components at the same time, and ingestion of each of the two components separately without taking time.

Testicular extract can also be added to cells, for example, at a concentration of 0.1 mg / ml or higher, preferably 0.5 mg / ml or higher, and added at a concentration of 0.75 mg / ml or higher. For example, it is more preferable to add at a concentration of 1 mg / ml or more. In any case, it may be added at a concentration of 50 mg / ml or less, preferably at a concentration of 20 mg / ml or less, preferably at a concentration of 10 mg / ml or less, for example, 8 adding at a concentration of mg / ml or less,
It is more preferable to add at a concentration of 5 mg / ml or less.

  Soy isoflavone can also be added to cells at a concentration of, for example, 5 μM or more, preferably at a concentration of 12.5 μM or more, and added at a concentration of 25 μM or more, for example, a concentration of 30 μM or more, 40 μM. It is more preferable to add at the above concentration or a concentration of 50 μM or more. In any case, it may be added at a concentration of 200 μM or less, preferably at a concentration of 100 μM or less, and at a concentration of 90 μM or less, for example, 80 μM or less, 75 μM or less, 70 μM or less. It is more preferable to add at a concentration.

  When combining soy isoflavone and testicular extract, when testicular extract is added to cells at a concentration of 0.01 to 5 mg / ml or more, soy isoflavone can be added at a concentration of 14 to 350 μM, It is preferably added at a concentration of 200 μM, more preferably at a concentration of 20 to 95 μM, further preferably at a concentration of 25 to 85 μM, and further preferably at a concentration of 50 to 80 μM.

〔Composition〕
The composition of the present invention can be a food composition, a pharmaceutical composition or a cosmetic composition. Preferably, it is taken orally, that is, a food composition or a pharmaceutical composition for oral administration. In the following description, the composition of the present invention may be described as an example of a food composition. However, those skilled in the art can understand the description by appropriately applying the description to a composition other than food. Further, in the present invention, the term “ingestion” may be used assuming that the composition is a food, but “ingestion” means “administration” (mainly in the case of pharmaceuticals), depending on the form of the composition, It can be replaced with “use” (mainly in the case of cosmetics).

  Food includes solid oral intake as well as liquid oral intake such as beverages and soups. Foods also include general foods (including so-called health foods, supplements, drinks, and jelly drinks. They may be labeled as dietary supplements, health supplements, and nutritionally adjusted foods), health functional foods (functional label foods) , Foods with functional nutrition, and foods for specified health use. Therapeutic meals (those that serve the purpose of treatment. Prepared by a doctor and prepared according to a menu prepared by a dietitian), dietary meals, ingredient-adjusted meals, low-salt meals, nursing meals Including reduced-calorie diet and diet diet. In addition to the form ingested as it is, it includes those used as food ingredients such as food ingredients. In addition to those for humans, those for non-human animals (pet food, animal supplements, feed, etc.) are also included.

  Examples of the form of the food composition of the present invention include powders, fine granules, granules, tablets, capsules, liquid preparations (elixirs, limonades, syrups, emulsions, suspensions, solutions, drinks. A gel-like agent, a therapeutic food, a beverage, a confectionery, a processed meat product, a processed fish product, a processed vegetable product, a side dish, a seasoning composition, and a food additive.

  The food composition of the present invention may contain other components other than the active ingredients as long as the desired effect can be exhibited. The other ingredients may be various food acceptable additives or various pharmaceutically acceptable additives. Examples include excipients, anti-oxidants (oxidants), flavorings, seasonings, sweeteners, colorants, thickeners, color formers, bleaches, fungicides, gum bases, bitters, etc. Enzymes, brighteners, acidulants, emulsifiers, reinforcing agents, production agents, binders, tonicity agents (isotonic agents), buffers, solubilizers, preservatives, stabilizers, coagulants, and the like.

  The other component may be a functional component other than the active component. Examples of other functional components include amino acids (eg, branched chain amino acids, ornithine), unsaturated fatty acids (eg, EPA, DHA), vitamins, trace metals, glucosamine, chondroitin, etc. .

  When the composition of the present invention comprises an active ingredient and other ingredients other than the active ingredient, the content of the active ingredient can be appropriately designed by those skilled in the art in terms of ease of manufacture, ease of use, and the like. 0.1 to 99.9%, 1 to 95%, 10 to 90%, and 51 to 90% or more.

  The content of soybean isoflavones and testicle extract as active ingredients in the composition of the present invention can be appropriately designed by those skilled in the art.

  The testicular extract content in the composition can be, for example, 1 mg per day of the composition, preferably 5 mg, more preferably 10 mg or more, and 20 mg or more. More preferably. Further, it may be 25 mg or more, 50 mg or more, 100 mg or more, or 200 mg or more. In either case, the daily intake may be 1,000 mg or less, or may be 400 mg or less.

  The content of soybean isoflavone in the composition can be, for example, 5 mg or more per day intake of the composition, preferably 10 mg or more, more preferably 15 mg or more, 20 More preferably, it is at least mg. Regardless of the lower limit, it can be 180 mg or less, preferably 120 mg or less, more preferably 60 mg or less, and even more preferably 30 mg or less.

  When the composition contains a combination of soy isoflavone and testicular extract, the mass ratio of soy isoflavone and testicular extract can be 1: 0.3 to 7.0, and 1: 0.5 to 6. 0 is preferable, 1: 1.0 to 5.0 is more preferable, 1: 1.2 to 4.0 is further preferable, and 1: 1.3 to 2.0 is preferable. More preferably.

  The food composition of the present invention is a therapeutic food (meeting the purpose of treatment; a meal prepared by a doctor and cooked based on a menu prepared by a dietitian etc.), a diet food, an ingredient-adjusted food, Low-salt diet, nursing diet, reduced-calorie diet, diet diet, or sports diet (food for the purpose of enhancing the ability in aerobic exercise, food for the purpose of enhancing endurance in aerobic exercise, nutrition until the day of competition) Food for accumulating in the body, food for nourishment during competition, and food for the purpose of recovery from fatigue after the competition is included.) It can be designed in consideration of intake.

  The food composition of the present invention can be repeatedly ingested by the subject, and can be ingested by the subject over a long period of time. In particular, when treating metabolic syndrome, it may be preferable to take it on a daily basis.

  The food composition of the present invention can indicate that it can be used to enhance the expression of adiponectin, and can indicate that it is recommended for a specific subject to take. More specifically, it is suitable for subjects in whom enhanced expression of adiponectin is desirable, suitable for athletes, treatment of diseases or conditions associated with enhanced expression of adiponectin (eg, diabetes and circulation strongly associated with metabolic syndrome) It is possible to display information that contributes to organ diseases, neurodegenerative diseases such as dementia and Parkinson's disease, treatment of cancer), increased ability in aerobic exercise, and increased endurance in aerobic exercise. The labeling can be direct or indirect, and examples of direct labeling are descriptions on tangible objects such as the product itself, packages, containers, labels, tags, etc. Includes advertising and publicity activities through sites or means such as websites, storefronts, exhibitions, signboards, bulletin boards, newspapers, magazines, television, radio, mailings, e-mails, etc.

〔Production method〕
The composition of the present invention can be produced using various known techniques. The process of adjusting the active ingredient to a predetermined content or concentration can be applied at various stages of the production process. A person skilled in the art can appropriately design the production process for the composition of the present invention in consideration of solubility, stability, volatility, etc. of the active ingredient.

  EXAMPLES Hereinafter, although this invention is demonstrated using an Example, the range of this invention is not restricted to what was described in the Example.

[Experiment 1: Testicular extract]
P-testis (PT) (manufactured by Nippon Ham Co., Ltd.) produced from hog testicles as a raw material through the steps of enzymatic degradation, enzyme deactivation, filtration, concentration, sterilization, and drying was used.
The composition of PT is shown in the table below.

[Experiment 2: Evaluation of adiponectin expression enhancing effect]
(1) Method Using fat model cells, the effect of animal meat-derived components on adiponectin secretion was evaluated. Mouse-derived preadipocytes (3T3-L1 cells) were cultured under Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS in 5% CO _{2 and} 1 × per well in a collagen-coated 12-well plate After seeding with 10 ⁵ cells, the cells were cultured until they became confluent. The medium of cells that became confluent after 2-3 days was replaced with DMEM medium containing 0.5 mmol / L isobutylmethylxanthine, 1 mol / L dexamethasone, 10 g / mL insulin and 10% FBS. At that time, daidzein, raw materials A to J, pork testis extract powder (PT) and 13 kinds of components to which PBS was added as a control were also added to each well so as to have respective predetermined final concentrations. The concentration and details of each component are shown in Table 3. Two days later, the medium was replaced with a DMEM medium containing 10 g / mL insulin and 10% FBS to which each component was added, and the cells were cultured for 5 to 7 days while changing to the aforementioned medium every 2-3 days until measurement was performed.

  After completion of the culture, the medium was removed, 0.5 ml of TRIzol (Invitrogen) was added, the cells were thawed, and collected in a 1.5 ml Eppendorf tube. After standing at room temperature for 5 minutes, 0.1 ml of chloroform was added, and the mixture was stirred by vortexing for 10 seconds. After leaving still for 5 minutes, it centrifuged for 10 minutes at 15000 rpm and 4 degreeC, and collect | recovered only the transparent water layer carefully to a new eppen. 100% ethanol was added to this, and after pipetting well, the whole amount was added to the spin column and centrifuged at 10,000 rpm for 1 minute. Then, add 0.5 ml of Wash Buffer (Promega) to the spin column, repeat the washing operation by centrifuging at 10000 rpm for 1 minute twice, air-dry the spin column for several minutes, and then add Nuclease-free water to the 40 μl spin column. Further, total RNA was obtained by further centrifugation at 15000 rpm for 1 minute.

  Reverse transcription reaction was performed using ReverTra Ace qPCR RT Kit (TOYOBO). The protocol followed the manufacturer's protocol. Next, real-time PCR was performed using THUNDERBIRD SYBR qPCR Mix (TOYOBO). Using the adiponectin gene-specific primer and the control β-actin gene-specific primer, the measurement was performed in triplicate using the CFX96 Deep Well Real-Time System (BIO-RAD), and the results showed the expression of each adiponectin mRNA. It was expressed as the value divided by the expression of adiponectin mRNA of β-actin.

  Details of other food materials used in the experiment are shown in the table below.

(2) Results The results are shown in FIG. In PT, a remarkable adiponectin potentiating action was confirmed.

[Experiment 3: Comparison with daidzein]
(1) Method The adiponectin concentration in the culture supernatant when the meat-derived component was added to the cells was evaluated. Cells were prepared in the same manner as in Experiment 2, and the culture supernatant collected at the end of the culture was measured using a mouse / rat adiponectin ELISA kit (Otsuka Pharmaceutical).
(2) Results The results are shown in FIG. PT enhanced adiponectin expression in a concentration-dependent manner up to 5 mg / ml, which exceeded the effect of daidzein.

[Experiment 4: Evaluation of effects by combination]
(1) Method The difference in adiponectin expression was evaluated between those treated with daidzein alone and those treated with daidzein and PT simultaneously. From the seeding of cells to real-time PCR and ELISA according to the methods of Experiments 2 and 3.

(2) Results The results are shown in FIG. Simultaneous addition of daidzein and PT synergistically enhanced adiponectin expression. The concentrations of daidzein and PT in the experiment and the mass ratio of PT to daidzein are summarized in the table below.

[Production example]
(1) Capsules After mixing 0.3 parts by weight of soy isoflavone, 0.9 parts by weight of pork testicle extract obtained in Experiment 1 above and 1.3 parts by weight of lactose, the capsules were hardened according to a conventional method. To produce a capsule having an internal volume of 250 mg (30 mg of soy isoflavone, 90 mg of pork testicle extract / capsule, 1 recommended daily intake).

(2) Tablets Maltose, dextrin, starch, vitamin E-containing direct oil, isomaltoligosaccharide, indigestible dextrin, shellfish calcium, trehalose, sucrose ester, vitamin C, citric acid, calcium phosphate, fragrance, shellac, niacin, vitamin Contains 10 mg soy isoflavone and 50 mg pork testis extract per tablet (300 mg) with K, sweetener, potassium chloride, vitamin A, calcium pantothenate, biotin, iron pyrophosphate, vitamin B, vitamin D, magnesium carbonate, and folic acid Make tablets (3 recommended daily intake).

(3) Sports drink A total of 20 g of sweeteners, vitamins, isotonic mix, etc., citric acid 0.2 g, flavor 0.1 g, soy isoflavone, and 0.01 g of pork testicle extract obtained in Experiment 1 are mixed with water. In addition, the total amount is 100 parts by weight, and a beverage is prepared by a conventional method to prepare a 500 ml container-packed beverage (soy isoflavone 15 mg, pork testicle extract 35 mg / 500 ml).

(4) Gelling agent 8 parts by weight of granulated sugar and 6 parts by weight of thickening polysaccharide were mixed in advance, 2 parts by weight of gelatin hydrolyzate and an appropriate amount of water were added and dissolved by heating. After removing heat, 10 parts by weight of isotonic mix, 0.1 part by weight of flavor, 0.02 part by weight of soy isoflavone and pork testicle extract obtained in Experiment 1, 0.09 part by weight of vitamin mix, 0 citric acid Add 3 parts by weight to make the total amount 100 parts by weight, and manufacture a gel of 150 g per serving by a conventional method (10 mg of soy isoflavone, 20 mg / 150 ml of swine testicle extract).

Claims (6)

A composition for enhancing adiponectin expression, comprising testicular extract. The composition of claim 1 further comprising soy isoflavones. The composition of Claim 2 or Claim 3 whose mass ratio of a soybean isoflavone and a testicle extract is 1: 0.3-7.0. A combination of soy isoflavone and testicular extract for enhancing adiponectin expression. The combination of Claim 4 whose mass ratio of a soybean isoflavone and a testicle extract is 1: 0.3-7.0. 6. A composition or combination according to any one of claims 1-5 for the treatment of metabolic syndrome and associated diabetes and cardiovascular disease.

Images